原发性骨髓纤维化伴环状铁粒幼红细胞增多患者的临床特征及预后分析
- 1 中国医学科学院血液病医院(中国医学科学院血液学研究所),血液与健康全国重点实验室,国家血液系统疾病临床医学研究中心,细胞生态海河实验室,天津 300020
- 2 天津医学院健康研究院,天津 301600
*通信作者
摘要
目的 本研究旨在探讨原发性骨髓纤维化(PMF)伴环状铁粒幼红细胞增多(RS)患者的临床、分子学特征及预后意义。 方法 回顾性分析2008年11月至2024年11月于中国医学科学院血液病医院确诊的826例PMF患者的临床及分子学特征。采用Kaplan-Meier法及多因素Cox回归模型进行生存预后分析。 结果 (1)PMF伴RS≥5%患者的临床与分子学特征:与PMF伴RS<5%组(n=775)相比,PMF伴RS≥5%组(n=51)的血红蛋白显著降低(103 vs. 79 g/L,P = 0.001),血清铁蛋白(142 vs. 369 ng/mL,P < 0.001)显著升高,骨髓纤维化≥2级(78.1% vs. 92.2%,P = 0.013)占比显著升高。基因突变分析方面,相比于RS<5%组,RS≥5%组CALR突变比例显著降低(26.2% vs. 11.8%,P = 0.021),SF3B1与SRSF2的突变比例显著升高(分别为4.7% vs. 27.5%,P < 0.001;6.4% vs. 17.5%,P = 0.007)。(2)PMF伴SF3B1突变患者的临床及分子学特征:相比于PMF中SF3B1阴性组(n=742),SF3B1阳性组(n=46)年龄更高,血红蛋白显著降低(105 vs. 82 g/L,P < 0.001),血清铁蛋白显著升高(143 vs. 311 ng/mL,P = 0.005),骨髓原始细胞≥5%(5.8% vs. 23.9%,P = 0.009)、骨髓纤维化分级≥2级(77.8% vs. 93.5%,P < 0.001)及异常核型(24.0% vs. 43.2%,P = 0.009)的患者比例均显著增高。SF3B1突变热点主要为p.K666位点(47.1%),其次是p.K700E(25.5%)。(3)预后分析:RS≥5%组的中位总生存时间显著短于RS<5%组(50个月 vs. 未达到,P < 0.001),3年预期生存率明显降低(51.2% vs. 74.7%)。SF3B1阳性组的3年预期生存率低于阴性组(53.8% vs. 74.7%,P=0.002)。将RS≥5%、SF3B1突变和突变强化国际预后评分系统(MIPSS70)预后分组,进行多因素Cox回归分析显示SF3B1突变[风险比(HR) = 1.892,95%置信区间(CI): 1.114~3.213,P = 0.018]是独立于MIPSS70预后分组(P < 0.001)的不良预后因素,而RS≥5%未见独立预后意义(P = 0.103)。 结论 PMF伴RS≥5%或SF3B1患者表现为更严重贫血、铁蛋白增高、明显骨髓纤维化等高危临床亚型;伴SF3B1突变是PMF患者生存的独立不良预后因素。
Clinical characteristics and prognostic analysis of primary myelofibrosis with increased ring sideroblasts
- 1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
- 2 Tianjin Institutes of Health Science, Tianjin 301600, China
*Corresponding author
Abstract
Objective To investigate the clinical and molecular characteristics, as well as the prognostic significance, of primary myelofibrosis (PMF) patients with ring sideroblasts (RS). Methods A retrospective cohort study was conducted, enrolling 826 patients diagnosed with PMF at the Institute of Hematology and Blood Diseases Hospital from November 2008 to November 2024. Survival and prognostic analyses were performed using the Kaplan-Meier method and multivariate Cox proportional hazards regression models. Results (1) Clinical and molecular features of PMF with RS ≥ 5%: Compared to the RS < 5% group (n = 775), the RS ≥ 5% group (n = 51) exhibited significantly lower hemoglobin levels (103 vs. 79 g/L, P = 0.001), higher serum ferritin levels (142 vs. 369 ng/mL, P < 0.001), and a higher proportion of myelofibrosis grade ≥ 2 (78.1% vs. 92.2%, P = 0.013). Regarding mutational profiles, the RS ≥ 5% group had a significantly lower frequency of CALR mutations than the RS < 5% group (11.8% vs. 26.2%, P = 0.021), but higher frequencies of SF3B1 (27.5% vs. 4.7%, P < 0.001) and SRSF2 mutations (17.5% vs. 6.4%, P = 0.007). (2) Clinical and molecular features of SF3B1-mutated PMF: Compared to the SF3B1 wild-type group (n = 742), the SF3B1-mutated group (n = 46) was older and presented with significantly lower hemoglobin levels (105 vs. 82 g/L, P < 0.001), higher serum ferritin levels (143 vs. 311 ng/mL, P = 0.005), and higher proportions of bone marrow blasts ≥ 5% (23.9% vs. 5.8%, P = 0.009), myelofibrosis grade ≥ 2 (77.8% vs. 93.5%, P < 0.001), and abnormal karyotypes (24.0% vs. 43.2%, P = 0.009). The most common SF3B1 mutation hotspot was p.K666 (47.1%), followed by p.K700E (25.5%). (3) Prognostic analysis: The median overall survival in the RS ≥ 5% group was significantly shorter than that in the RS < 5% group (50 months vs. not reached, P < 0.001), with a lower 3-year estimated survival rate (51.2% vs. 74.7%). Similarly, the SF3B1-mutated group had a significantly lower 3-year estimated survival rate compared to the wild-type group (53.8% vs. 74.7%, P = 0.002). Multivariate Cox regression analysis, incorporating RS ≥ 5%, SF3B1 mutations, and the MIPSS70 scoring system, revealed that the SF3B1 mutation [Hazard Ratio (HR) = 1.892, 95% confidence interval (CI): 1.114 ~ 3.213, P = 0.018] was an adverse prognostic factor independent of the MIPSS70(P < 0.001) , whereas RS ≥ 5% lost its independent prognostic significance (P = 0.103). Conclusion PMF patients with RS ≥ 5% or SF3B1 mutations represent a high-risk clinical subgroup characterized by more severe anemia, elevated ferritin, and more advanced myelofibrosis. The SF3B1 mutation is an independent adverse prognostic factor for survival in PMF patients.
